Acquired Hemostasis Disorders

Authors: Tufano, A; Franchini, M; Coppola, A

Affiliations: Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy. Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Parma, Italy.

Publication: Seminars in thrombosis and hemostasis; 2026; 52. 277–279

ABSTRACT: This latest issue of Seminars in Thrombosis and Hemostasis (STH) is dedicated to acquired disorders of hemostasis, a broad and evolving group of conditions that significantly contribute to morbidity and mortality across all medical and surgical settings. Their clinical presentation, secondary to systemic disease, immune dysregulation, critical illness, malignancy, pregnancy-related conditions, or iatrogenic factors, including antithrombotic and anticancer drugs, is often abrupt and heterogeneous, ranging from life-threatening bleeding to complex and diffuse thrombotic phenotypes. In recent years, major advances refined our understanding of the mechanisms underlying these disorders, particularly those driven by autoantibodies, endothelial dysfunction, inflammation, and consumptive coagulopathies, in parallel with progress in laboratory diagnostics (including global coagulation assays) and therapeutic options (targeted hemostatic agents, factor concentrates, and reversal strategies for direct oral anticoagulants). However, timely recognition and optimal management remain challenging in most acquired bleeding and thrombotic clinical conditions.